Five things for pharma marketers to know: Thursday, July 14, 2016

Five things for pharma marketers to know: Thursday, July 14, 2016

The FDA expands use for Pfizer's Prevnar 13 vaccine; an FDA panel votes in support of Novartis biosimilar; U.S. healthcare spending rises 5.5% in 2015

Five things for pharma marketers to know: Monday, July 11, 2016

Five things for pharma marketers to know: Monday, July 11, 2016

Purdue Pharma reportedly knew about OxyContin trafficking; Amgen's Repatha approved for monthly dosing option; Clinton proposes new healthcare measures

Five things for pharma marketers to know: Friday, July 8, 2016

Five things for pharma marketers to know: Friday, July 8, 2016

The FDA said Amgen's biosimilar of Humira is safe and effective; Juno trial halted due to patient deaths; the CMS bans Theranos founder

Five things for pharma marketers to know: Monday, June 27, 2016

Five things for pharma marketers to know: Monday, June 27, 2016

Former FDA commissioners said agency should be independent from HHS; Sanofi and BI confirm asset swap; FDA panel to vote on new Jardiance data

Five things for pharma marketers to know: Friday, June 24, 2016

Five things for pharma marketers to know: Friday, June 24, 2016

Brexit votes creates EU regulatory uncertainty; Obama plans to veto health saving accounts bill; broad Entresto adoption could prevent more than 28,000 deaths

Five things for pharma marketers to know: Thursday, June 23, 2016

Five things for pharma marketers to know: Thursday, June 23, 2016

Medicare cost-cutting panel will not be activated this year; more Americans are abusing opioids; BIO blasts ICER

Five things for pharma marketers to know: Thursday, June 16, 2016

Five things for pharma marketers to know: Thursday, June 16, 2016

A government watchdog criticizes the FDA; the FDA strengthens kidney warnings for Invokana and Farxiga; people with diabetes are living longer

Five things for pharma marketers to know: Tuesday, May 31, 2016

Five things for pharma marketers to know: Tuesday, May 31, 2016

Lawmaker calls for investigation of Purdue; Jazz to acquire Celator; Intercept's liver drug is approved

Five things for pharma marketers to know: Tuesday, May 24, 2016

Five things for pharma marketers to know: Tuesday, May 24, 2016

The FDA accepts Samsung's biosimilar for review; Sanofi retools executive committee; Entresto may get a boost from updated care guidelines

Five things for pharma marketers to know: Monday, May 23, 2016

Five things for pharma marketers to know: Monday, May 23, 2016

E.U. lifts warning on Pfizer's Chantix; Obama's Medicare Part B proposal panned by lawmakers; France to propose stricter rules for clinical trials

Industry criticizes FDA's proposed DTC studies

Industry criticizes FDA's proposed DTC studies

Pharma companies took issue with the methodology for the FDA's proposed studies of advertising tactics.

Lobbyists argue DTC ad tax deduction may be a casualty of reform

Lobbyists argue DTC ad tax deduction may be a casualty of reform

Advertising lobbyist said eliminating the DTC ad tax deduction is a real threat to the industry.

Five things for pharma marketers to know: Wednesday, May 4, 2016

Five things for pharma marketers to know: Wednesday, May 4, 2016

The FDA issues warning for certain antipsychotics; Shkreli may face more securities charges; Genentech and Stand Up to Cancer launch campaign

Five things for pharma marketers to know: Thursday, April 28, 2016

Five things for pharma marketers to know: Thursday, April 28, 2016

Pfizer settles rebate suit; Sanofi moves to acquire Medivation; AstraZeneca sells US rights to gout drug

Senate committee condemns Valeant's business model

Senate committee condemns Valeant's business model

The Senate committee on Aging said Valeant's missteps go beyond price hikes and that its business model is fundamentally to blame.